重症肝病合并感染的纳米抗菌治疗趋势  

Trends in nano-antimicrobial therapy for severe liver disease with infection

作　　者：罗珍群 罗新华[2] LUO Zhenqun;LUO Xinhua(School of Clinical Medicine,Zunyi Medical University,Zunyi,Guizhou 563000,China;Department of Infectious Diseases,Guizhou Provincial People’s Hospital,Guiyang 550000,China)

机构地区：[1]遵义医科大学临床医学院,贵州遵义563000 [2]贵州省人民医院感染科,贵阳550000

出　　处：《临床肝胆病杂志》2023年第3期713-717,共5页Journal of Clinical Hepatology

摘　　要：重症肝病合并感染一直是临床治疗的重点难点。研究者们通过对纳米材料的不断探索发现,纳米材料由于其特殊理化性质可实现靶向抗菌及免疫调节作用。从纳米材料无抗生素的靶向抗菌、纳米药物递送系统的靶向抗菌、靶向免疫调节治疗方面,结合新近文献进展对重症肝病合并感染相关的纳米治疗可能机制作一总结,拟为临床上有效治疗重症肝病合并感染提供新的治疗策略。Severe liver disease with infection has always been a key and difficult point in clinical treatment. Through continuous exploration of nanomaterials, researchers have found that nanomaterials can achieve targeted antibacterial and immunomodulatory effects due to their special physicochemical properties. With reference to recent articles and advances, this article reviews the possible mechanisms of nano-therapies for severe liver disease with infection from the aspects of targeted antibacterial effect of nanomaterials without antibiotics, targeted antibacterial effect of nano-drug delivery systems, and targeted immunomodulatory therapy, so as to provide new treatment strategies for the prevention and treatment of severe liver disease with infection in clinical practice.

关 键 词：肝疾病 感染 纳米粒子 

分 类 号：R575[医药卫生—消化系统]